Provided by Tiger Fintech (Singapore) Pte. Ltd.

Galectin Therapeutics

1.32
-0.1000-7.04%
Volume:157.03K
Turnover:211.16K
Market Cap:83.40M
PE:-1.74
High:1.41
Open:1.40
Low:1.28
Close:1.42
Loading ...

Galectin Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

TIPRANKS
·
28 Dec 2024

Galectin Therapeutics Shares Drop 54% After Treatment Misses Trial Endpoint

Dow Jones
·
21 Dec 2024

Top Midday Decliners

MT Newswires
·
21 Dec 2024

Dow Surges 100 Points, Carnival Earnings Top Views

Benzinga
·
20 Dec 2024

Galectin Therapeutics Shares Fall 35.5% After Liver Disease Drug Fails to Meet Main Goal in Study

THOMSON REUTERS
·
20 Dec 2024

BRIEF-Galectin Therapeutics Inc - Belapectin Well Tolerated With No Safety Signals

Reuters
·
20 Dec 2024

Galectin's Belapectin Study Shows Mixed Endpoint Results; Shares Fall Pre-Bell

MT Newswires Live
·
20 Dec 2024

BUZZ-Galectin Therapeutics falls after liver disease drug fails to meet main goal in study

Reuters
·
20 Dec 2024

Galectin Therapeutics Shares Fall 50% Premarket After Liver Disease Drug Fails to Meet Main Goal in Study

THOMSON REUTERS
·
20 Dec 2024

Galectin Therapeutics announces results from NAVIGATE trial on belapectin

TIPRANKS
·
20 Dec 2024

Galectin Therapeutics Inc - Belapectin Did Not Achieve Statistical Significance in ITT Population

THOMSON REUTERS
·
20 Dec 2024

Galectin Therapeutics Announces Top-Line Results of Navigate Clinical Trial Evaluating Belapectin in Patients With Cirrhotic Portal Hypertension Caused by Mash

THOMSON REUTERS
·
20 Dec 2024

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

GlobeNewswire
·
20 Dec 2024

Galectin Therapeutics Inc - Belapectin Did Not Achieve Statistical Significance in Intent-to-Treat Population

THOMSON REUTERS
·
20 Dec 2024

Galectin Therapeutics Inc - Belapectin Well Tolerated With No Safety Signals

THOMSON REUTERS
·
20 Dec 2024

Galectin Therapeutics Inc - Belapectin Shows Significant Reduction in Esophageal Varices in 2Mg/Kg Cohort

THOMSON REUTERS
·
20 Dec 2024

Here's Why Galectin Therapeutics (GALT) is Poised for a Turnaround After Losing -31.83% in 4 Weeks

Zacks
·
09 Dec 2024

Galectin Therapeutics presents three abstracts at AASLD 2024 Liver Meeting

TIPRANKS
·
18 Nov 2024

Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

GlobeNewswire
·
18 Nov 2024

Galectin Therapeutics Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
15 Nov 2024